Publications

5674 Results

Phase III trials in patients with advanced stage non-small cell lung cancer (NSCLC) from 1973-1994

Authors
BE Johnson;B Freidlin;B Conley;MR Green;DJ Johnson;DR Gandara;MJ O'Connel;R Simon;OS Breathnach
Journal / Conference
Proc of the American Society of Clinical Oncology 19:488a(#1909)
Year
2000
Research Committee(s)
Lung

Predictive value of automated, quantitative real-time RT-PCR performed at the end of consolidation of acute promyelocytic leukemia (APL): a SWOG, CALGB, and ECOG Intergroup study (INT-0129)

Authors
CL Willman;B Yeap;W Bi;JC Slack;DP Harrington;KJ Livak;FR Appelbaum;CD Bloomfield;MS Tallman;RE Gallagher
Journal / Conference
Proc of the American Society of Clinical Oncology 19:5a(#9)
Year
2000
Research Committee(s)
Leukemia
Study Number(s)
SWOG-9129 (INT-0129)

Thioredoxin, a putative oncogene product is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival

Authors
TM Grogan;C Fenoglio-Prieser;R Zeheb;W Bellamy;Y Frutiger;E Vela;G Stemmerman;J Macdonald;L Richter;A Gallegos;G Powis
Journal / Conference
Human Pathology 31(4):475-481
Year
2000
Research Committee(s)
Gastrointestinal
Study Number(s)
SWOG-9008 (INT-0116) (RTOG-9018) (NCCTG-90-41-51) (ECOG-6290) (CALGB-9195)

Clinical correlation for colorectal cancers with microsatellite instability (MSI)

Authors
DP Chauhan;LC Lovato;A Goel;T Aoki;CR Boland;DJ Ahnen
Journal / Conference
Gastroenterology 118(4)Suppl:A58(#499)
Year
2000
Research Committee(s)
Gastrointestinal
Study Number(s)
SWOG-8591(NCI Intergroup #0035)

A protocol for triple color interphase FISH on archived bone marrow biopsies from myeloma prepared with precipitating fixatives

Authors
E Tian;K Bumm;Y Xiao;H Xu;A Li;E Williamson;B Barlogie;J Sawyer;J Shaughnessy
Journal / Conference
Blood 96(11):155a(#665)
Year
2000
Research Committee(s)
Myeloma
Study Number(s)
SWOG-9321

BETA 2 microglobulin (O2M) and plasma cell labeling index (PCLI) constitute a strong prognostic index in the SWOG Intergroup transplant trial S9321: Observations on gender and age

Authors
PR Greipp;JL Jacobson;JJ Crowley;KJ Henderson;KC Anderson;RA Kyle;B Barlogie
Journal / Conference
Blood 96(11):152a(#653)
Year
2000
Research Committee(s)
Myeloma
Study Number(s)
SWOG-9321

Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm)

Authors
CM Balch;SJ Soong;MI Ross;MM Urist;CP Karakousis;WJ Temple;MC Mihm;RL Barnhill;WR Jewell;HJ Wanebo;R Harrison
Journal / Conference
Annals of Surgical Oncology 7(2):87-97
Year
2000
Research Committee(s)
Melanoma
Study Number(s)
SWOG-8393 (INT-0013)

Hypergranular promyelocytic leukemia: correlation between morphology and chromosomal translocations including t(15;17) and t(11;17)

Authors
JM Bennett;D Catovsky;MT Daniel;G Flandrin;D Galton;HR Gralnick;CL Willman
Journal / Conference
Leukemia 14:1197-1200
Year
2000
Research Committee(s)
Leukemia
Study Number(s)
SWOG-9129 (INT-0129)

SWOG-9035: adjuvant therapy of intermediate-thickness node-negative melanoma with an allogeneic tumor vaccine.

Authors
VK Sondak;PY Liu;RJ Tuthill;RA Kempf;JM Unger;JA Sosman;JA Thompson;GR Weiss;BG Redman;JG Jakowatz;RD Noyes;LE Flaherty
Journal / Conference
Journal of Immunotherapy 23(5):600
Year
2000
Research Committee(s)
Melanoma
Study Number(s)
SWOG-9035

Class I HLA serotyping in T3NO melanoma patients entered onto SWOG 9035: a phase III trial of melacine TM (allogeneic tumor lysate vaccine) vs observation.

Authors
JA Sosman;JM Unger;PY Liu;L Flaherty;J Thompson;VK Sondak
Journal / Conference
Journal of Immunotherapy 23(5):605
Year
2000
Research Committee(s)
Melanoma
Study Number(s)
SWOG-9035